Lead Product(s): CT120
Therapeutic Area: Oncology Product Name: CT120
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2021
CT120 is an autologous dual-target CAR-T therapy. Its extra cellular domain contains two fully-human scFv sequences that can specifically recognize CD19 and CD22. CT120 is developed on IASO Bio’s fully human antibody platform IMARS and CAR-T drug selection platform.